TSX:NUMI - Toronto Stock Exchange - CA67054W1032 - Common Stock - Currency: CAD
TSX:NUMI (1/29/2025, 7:00:00 PM)
0.05
+0.02 (+42.86%)
The current stock price of NUMI.CA is 0.05 CAD. In the past month the price increased by 25%. In the past year, price decreased by -58.33%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
WEED-DB.CA | CANOPY GROWTH CORP | N/A | 9.54B | ||
BHC.CA | BAUSCH HEALTH COS INC | 1.41 | 2.71B | ||
CRON.CA | CRONOS GROUP INC | 18.5 | 998.21M | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 684.42M | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 5.3 | 647.57M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | 121.6 | 604.66M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 399.25M | ||
ACB.CA | AURORA CANNABIS INC | 27.83 | 351.10M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 21.13 | 346.38M | ||
HITI.CA | HIGH TIDE INC | N/A | 268.72M | ||
TSND.CA | TERRASCEND CORP | N/A | 220.81M | ||
OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 216.72M |
Numinus Wellness, Inc. engages in the development of psychedelic-centered therapeutic products. The company is headquartered in Montreal, Quebec. The firm focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
NUMINUS WELLNESS INC
393 Laurier Ave W
MONTREAL QUEBEC V6B 1R4 CA
CEO: Payton Nyquvest
Employees: 0
Company Website: https://numinus.com/
Investor Relations: http://www.investors.numinus.com/overview/default.aspx
Phone: 18336864687.0
The current stock price of NUMI.CA is 0.05 CAD. The price increased by 42.86% in the last trading session.
The exchange symbol of NUMINUS WELLNESS INC is NUMI and it is listed on the Toronto Stock Exchange exchange.
NUMI.CA stock is listed on the Toronto Stock Exchange exchange.
NUMINUS WELLNESS INC (NUMI.CA) has a market capitalization of 16.12M CAD. This makes NUMI.CA a Nano Cap stock.
NUMINUS WELLNESS INC (NUMI.CA) currently has 0 employees.
NUMINUS WELLNESS INC (NUMI.CA) has a support level at 0.05. Check the full technical report for a detailed analysis of NUMI.CA support and resistance levels.
The Revenue of NUMINUS WELLNESS INC (NUMI.CA) is expected to decline by -18.04% in the next year. Check the estimates tab for more information on the NUMI.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NUMI.CA does not pay a dividend.
NUMINUS WELLNESS INC (NUMI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
ChartMill assigns a technical rating of 4 / 10 to NUMI.CA. When comparing the yearly performance of all stocks, NUMI.CA turns out to be only a medium performer in the overall market: it outperformed 45.79% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to NUMI.CA. NUMI.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NUMI.CA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 37.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -213.24% | ||
ROE | -644.74% | ||
Debt/Equity | 0.95 |
ChartMill assigns a Buy % Consensus number of 83% to NUMI.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 58.33% and a revenue growth -18.04% for NUMI.CA